[TNF blocker infliximab receives award. Quality leap in therapy of chronic inflammatory diseases]
[Article in
German]
- PMID: 19960723
Item in Clipboard
[TNF blocker infliximab receives award. Quality leap in therapy of chronic inflammatory diseases]
[Article in
German]
MMW Fortschr Med.
.
No abstract available
Similar articles
-
[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].Ned Tijdschr Geneeskd. 2001 Nov 24;145(47):2294-5. Ned Tijdschr Geneeskd. 2001. PMID: 11760611 Dutch. No abstract available.
-
The role of tumor necrosis factor inhibitors in patients with RA.JAAPA. 2002 Sep;15(9):23-4, 27, 30 passim. JAAPA. 2002. PMID: 12395668 No abstract available.
-
Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.Rheumatology (Oxford). 2006 Oct;45(10):1314-5. doi: 10.1093/rheumatology/kel211. Epub 2006 Jul 11. Rheumatology (Oxford). 2006. PMID: 16837474 No abstract available.
-
Infliximab treatment of rheumatoid arthritis.Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. doi: 10.1016/j.rdc.2004.01.009. Rheum Dis Clin North Am. 2004. PMID: 15172044 Review.
-
Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).Int J Clin Pract. 2001 Apr;55(3):211-6. Int J Clin Pract. 2001. PMID: 11351775 Review.